Nipro Corporation
VC Fund
Osaka, Japan
Nipro Corporation is a Japanese medical equipment manufacturing company. Founded in 1954, the company is headquartered in Osaka and is listed on the Tokyo Stock Exchange and the Osaka Securities Exchange.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Nipro Corporation invests in
Stages Nipro Corporation invests in
Countries Nipro Corporation invests in
Investment Focus
Industry
- Health Care 2 (100%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
- Medical Device 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Country
- Ireland 1 (50%)
- United Kingdom 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Venari Medical’s mission focus is on the innovation of unparalleled safe, effective, patient-centered medical devices that improve quality of life for those with debilitating vascular disease.Venari Medical are developing BioVena™ - a more effective, less invasive, and faster treatment for all venous disease patients. It is uniquely positioned todisrupt current treatment practices which have seen only medium level innovation in the past decade. The team is based at Ireland's medtech cluster in Galway.Only 1.3 million of the 120 million people in the US & EU who suffer from venous disease currently receive endovenous treatment each year. 3 million venous ulcer patients are completely unserved, using ineffective compression bandaging. Venari Medical offers an unrivaled lower risk and unparalleled effective non-thermal treatment which will allow more patients who suffer from Venous Disease to access effective treatment.The indication for the use of superficial venous ablation is also set to widen to treat venous ulcers that currently incur annual costs of $33Bn to insurers in the US & EU. The Venari Medical technology can be used as a safe and effective treatment for the whole spectrum of Venous Disease from varicose veins to active venous ulcers. | $5.3M / Seed / Oct 28, 2020 | ||
| TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life.TC BioPharm is a clinical development company with a cell-based product pipeline capable oftreating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients. | $7.9M / Series A / Jan 31, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nipro Corporation invest in?
Nipro Corporation invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nipro Corporation last invest?
The most recent investment recorded for Nipro Corporation closed in Oct 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
